Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
EMERYVILLE, Calif., Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 2:35 p.m. ET.
加利福尼亞州埃默裏維爾，2024年11月26日 /PRNewswire/ — 開發和商業化創新疫苗的商業階段生物製藥公司戴納瓦克斯科技公司（納斯達克股票代碼：DVAX）今天宣佈，該公司將於美國東部時間12月3日星期二下午2點35分出席第七屆Evercore HealthConx年度會議。
The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at .
該演示將進行網絡直播，可通過公司網站 「投資者」 部分的 「活動與演講」 頁面進行訪問，網址爲。
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018 adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit .
關於 Dynavax
Dynavax是一家處於商業階段的生物製藥公司，正在開發和商業化創新疫苗，以幫助保護世界免受傳染病的侵害。該公司有兩種商業產品，HepliSav-B疫苗 [乙型肝炎疫苗（重組），佐劑]，已獲美國、歐盟和英國批准，用於預防18歲及以上成年人由所有已知的乙型肝炎病毒亞型引起的感染，以及CpG 1018佐劑，目前用於 HeplisaV-B 和多種佐劑 COVID-19 疫苗。有關我們的上市產品和開發渠道的更多信息，請訪問。
For Investors/Media:
Paul Cox
[email protected]
510-665-0499
對於投資者/媒體：
保羅·考克斯
[電子郵件保護]
510-665-0499
Nicole Arndt
[email protected]
510-665-7264
妮可·阿恩特
[電子郵件保護]
510-665-7264
SOURCE Dynavax Technologies
來源 Dynavax 科技
